tetano
Editor, Senior Moderator
Curr Opin Infect Dis. 2019 Feb 4. doi: 10.1097/QCO.0000000000000532. [Epub ahead of print]
[h=1]Influenza virus polymerase inhibitors in clinical development.[/h] Hayden FG[SUP]1[/SUP], Shindo N[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE OF REVIEW:[/h] We review antivirals inhibiting subunits of the influenza polymerase complex that are advancing in clinical development.
[h=4]RECENT FINDINGS:[/h] Favipiravir, pimodivir, and baloxavir are inhibitory in preclinical models for influenza A viruses, including pandemic threat viruses and those resistant to currently approved antivirals, and two (favipiravir and baloxavir) also inhibit influenza B viruses. All are orally administered, although the dosing regimens vary. The polymerase basic protein 1 transcriptase inhibitor favipiravir has shown inconsistent clinical effects in uncomplicated influenza, and is teratogenic effects in multiple species, contraindicating its use in pregnancy. The polymerase basic protein 2 cap-binding inhibitor pimodivir displays antiviral effects alone and in combination with oseltamivir in uncomplicated influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Single doses of the polymerase acidic protein cap-dependent endonuclease inhibitor baloxavir are effective in alleviating symptoms and rapidly inhibiting viral replication in otherwise healthy and higher risk patients with acute influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Combinations of newer polymerase inhibitors with neuraminidase inhibitors show synergy in preclinical models and are currently undergoing clinical testing in hospitalized patients.
[h=4]SUMMARY:[/h] These new polymerase inhibitors promise to add to the clinical management options and overall control strategies for influenza virus infections.
PMID: 30724789 DOI: 10.1097/QCO.0000000000000532
[h=1]Influenza virus polymerase inhibitors in clinical development.[/h] Hayden FG[SUP]1[/SUP], Shindo N[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE OF REVIEW:[/h] We review antivirals inhibiting subunits of the influenza polymerase complex that are advancing in clinical development.
[h=4]RECENT FINDINGS:[/h] Favipiravir, pimodivir, and baloxavir are inhibitory in preclinical models for influenza A viruses, including pandemic threat viruses and those resistant to currently approved antivirals, and two (favipiravir and baloxavir) also inhibit influenza B viruses. All are orally administered, although the dosing regimens vary. The polymerase basic protein 1 transcriptase inhibitor favipiravir has shown inconsistent clinical effects in uncomplicated influenza, and is teratogenic effects in multiple species, contraindicating its use in pregnancy. The polymerase basic protein 2 cap-binding inhibitor pimodivir displays antiviral effects alone and in combination with oseltamivir in uncomplicated influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Single doses of the polymerase acidic protein cap-dependent endonuclease inhibitor baloxavir are effective in alleviating symptoms and rapidly inhibiting viral replication in otherwise healthy and higher risk patients with acute influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Combinations of newer polymerase inhibitors with neuraminidase inhibitors show synergy in preclinical models and are currently undergoing clinical testing in hospitalized patients.
[h=4]SUMMARY:[/h] These new polymerase inhibitors promise to add to the clinical management options and overall control strategies for influenza virus infections.
PMID: 30724789 DOI: 10.1097/QCO.0000000000000532